iRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS grew 97.7%, free cash flow grew 117.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow IRTC
iRhythm Holdings, Inc. (IRTC) EV/Sales
As of 16 October 2026, iRhythm Holdings, Inc. (IRTC) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from 1.1× (November 2016) to 28.7× (November 2020); the current reading is higher than 9% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.7× | 55.33% |
| FY2024 | 5.0× | (18.72%) |
| FY2023 | 6.1× | (5.30%) |
| FY2022 | 6.4× | (35.68%) |
| FY2021 | 10.0× | (57.71%) |
| FY2020 | 23.7× | 214.75% |
| FY2019 | 7.5× | (31.48%) |
| FY2018 | 11.0× | (11.80%) |
| FY2017 | 12.5× | 843.00% |
| FY2016 | 1.3× | 13.21% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.8× | (3.69%) |
| Mar 2026 | 5.0× | (34.94%) |
| Dec 2025 | 7.7× | (3.82%) |
| Sep 2025 | 8.0× | 4.48% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIVN LivaNova PLC compare | 2.7× |
| ITGR Integer Holdings Corporation compare | 3.0× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| IRTC iRhythm Holdings, Inc. | 4.4× |
| HAE Haemonetics Corporation compare | 4.7× |
| AXGN AxoGen, Inc. compare | 7.0× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)